479-20-9
Chemical Structure
Atranorin
- CAS No.: 479-20-9
- Formula:C19H18O8
- Molecular Weight:374.34
IUPAC Name: 3-hydroxy-4-(methoxycarbonyl)-2,5-dimethylphenyl 3-formyl-2,4-dihydroxy-6-methylbenzoate
InChIKey: YLOYKYXNDHOHHT-UHFFFAOYSA-N
SMILES: O=C(OC1=CC(C)=C(C(OC)=O)C(O)=C1C)C2=C(C)C=C(O)C(C=O)=C2O
Biological Activity: Atranorin is a secondary metabolite of lichens and AKT inhibitor. Atranorin possesses multiple activities such as antibacterial, anti-inflammatory, antioxidant, anti-glycation, analgesic, and anti-tumor effects. Atranorin has IC50 values for scavenging DPPH and ABTS free radicals of 117 μM and less than 10 μM, respectively. Additionally, Atranorin also exhibits effects in promoting wound healing. Atranorin can be used in the research of various diseases, including myelodysplastic syndromes, tumors, and inflammatory conditions[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Atranorin | 99.68% | Atranorin is a secondary metabolite of lichens and AKT inhibitor. Atranorin possesses multiple activities such as antibacterial, anti-inflammatory, antioxidant, anti-glycation, analgesic, and anti-tumor effects. Atranorin has IC50 values for scavenging DPPH and ABTS free radicals of 117 μM and less than 10 μM, respectively. Additionally, Atranorin also exhibits effects in promoting wound healing. Atranorin can be used in the research of various diseases, including myelodysplastic syndromes, tumors, and inflammatory conditions. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Atranorin (Standard) | ≥98% | Atranorin (Standard) is the analytical standard of Atranorin (HY-N2907). This product is intended for research and analytical applications. Atranorin is a secondary metabolite of lichens and AKT inhibitor. Atranorin possesses multiple activities such as antibacterial, anti-inflammatory, antioxidant, anti-glycation, analgesic, and anti-tumor effects. Atranorin has IC50 values for scavenging DPPH and ABTS free radicals of 117 μM and less than 10 μM, respectively. Additionally, Atranorin also exhibits effects in promoting wound healing. Atranorin can be used in the research of various diseases, including myelodysplastic syndromes, tumors, and inflammatory conditions. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Melo MG, et al. Redox properties and cytoprotective actions of atranorin, a lichen secondary metabolite. Toxicol In Vitro. 2011 Mar;25(2):462-8. [Content Brief]
- [2]. Semenov K N, et al. Atranorin is a novel potential candidate drug for treating myelodysplastic syndrome. Journal of Molecular Liquids, 2024, 413: 125743.
- [3]. Zhou R, et al. The lichen secondary metabolite atranorin suppresses lung cancer cell motility and tumorigenesis. Sci Rep. 2017 Aug 15;7(1):8136. [Content Brief]
- [4]. Barreto R S S, et al. Evaluation of wound healing activity of atranorin, a lichen secondary metabolite, on rodents. Revista Brasileira de Farmacognosia, 2013, 23(2): 310-319.
- [5]. Ranković B, et al. The antimicrobial activity of substances derived from the lichens Physcia aipolia, Umbilicaria polyphylla, Parmelia caperata and Hypogymnia physodes. World journal of microbiology and biotechnology, 2008, 24: 1239-1242.
Keywords